An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
Completed · Phase 3 · Has a placebo group
Conditions studied: Major Depressive Disorder
In brief
The main purpose of this study is to evaluate the efficacy of saredutant 100mg once daily in combination with escitalopram 10mg once daily compared to saredutant placebo in combination with escitalopram 10mg once daily in patients with major depressive disorder. This study also includes a double-placebo group (saredutant placebo in combination with escitalopram placebo).
Key facts
- Study ID
- NCT00531622
- Run by
- Sanofi
- People needed
- 643
- Starts
- 2007-09-01
- Expected to finish
- 2009-01-01
- Last updated by the study team
- 2016-05-24
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Outpatients with recurrent Major Depressive Disorder
You may not qualify if…
- Symptoms of current depressive episode for less than 30 days or more than 2 years
- Mild depression, as measured by standard clinical research scales
- Significant suicide risk
- Lack of sexual activity (including masturbation)
- Other psychiatric conditions that would obscure the results of the study
- History of failure to respond to antidepressant treatment
- Pregnancy or breast-feeding
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Where it is running
- Sanofi-Aventis Administrative Office — Bridgewater, New Jersey, United States
- Sanofi-Aventis Administrative Office — Buenos Aires, Argentina
- Sanofi-Aventis Administrative Office — Helsinki, Finland
- Sanofi-Aventis Administrative Office — Paris, France
- Sanofi-Aventis Administrative Office — México, Mexico
- Sanofi-Aventis Administrative Office — Bromma, Sweden
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.